DUOLIN Rotacaps (Levosalbutamol sulphate + Ipratropium bromide)
|
|
- Eugene Harper
- 6 years ago
- Views:
Transcription
1 Published on: 19 Sep 2014 DUOLIN Rotacaps (Levosalbutamol sulphate + Ipratropium bromide) Composition DUOLIN Rotacaps Each capsule contains: Levosalbutamol sulphate 100 mcg Ipratropium bromide.. 40 mcg Dosage Form Dry powder for inhalation Description DUOLIN rotacaps are a combination of ipratropium bromide and levosalbutamol sulphate. Ipratropium bromide is an anticholinergic (parasympatholytic) agent, which inhibits vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released from the vagus nerve. Levosalbutamol sulphate is a relatively selective beta 2 -adrenergic agonist, whose activation leads to an increase in intracellular adenyl cyclase, the enzyme which catalyses the conversion of adenosine triphosphate (ATP) to cyclic-3', 5'- adenosine monophosphate (camp). Pharmacology Pharmacodynamics No pharmacodynamic studies have been carried out on levosalbutamol sulphate and ipratropium bromide combination. Hence pharmacodynamics of levosalbutamol sulphate and ipratropium bromide has been discussed individually. Levosalbutamol Activation of beta 2 -adrenergic receptors on airways smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular concentration of camp. The increase in camp is associated with the activation of protein kinase A, which in turn, inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in muscle relaxation. Levosalbutamol relaxes the smooth muscles of all airways, from the trachea to the terminal bronchioles. Increased camp concentrations are also associated with the inhibition of the release of mediators from mast cells in the airways. Levosalbutamol acts as a functional antagonist to relax the airways, irrespective of the spasmogen involved, thus protecting against all bronchoconstrictor challenges. While it is recognized that beta2-adrenergic receptors are the predominant receptors on bronchial smooth muscle, data indicate that there are beta-receptors in the human heart, 10-50% of which are beta2-adrenergic receptors. The precise function of these receptors has not been established. However, all beta-adrenergic agonist drugs can produce significant cardiovascular effects in some patients, as measured
2 by pulse rate, blood pressure, symptoms, and/or electrocardiographic changes. Ipratropium Bromide Ipratropium bromide is an anticholinergic (parasympatholytic) agent, which, based on animal studies, appears to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released from the vagus nerve. Anticholinergics prevent increases in the intracellular concentration of Ca ++, which are caused by the interaction of acetylcholine with the muscarinic receptors on bronchial smooth muscle. In clinical trials using metered-dose inhalers in patients with reversible bronchospasm associated with asthma or COPD, significant improvements in pulmonary function (FEV 1 increases of 15% or more) occurred within 15 minutes, reached a peak in 1 2 hours, and persisted for approximately 4 hours. Controlled clinical studies have demonstrated that does not alter either mucociliary clearance or the volume or viscosity of respiratory secretions. DUOLIN rotacaps are expected to maximize the response to treatment in patients with chronic obstructive pulmonary disease (COPD) by reducing bronchospasm through two distinctly different mechanisms: anticholinergic (parasympatholytic) and sympathomimetic. Simultaneous administration of both an anticholinergic (ipratropium bromide) and a beta 2 -sympathomimetic (levosalbutamol sulphate) is designed to benefit the patient by producing a greater bronchodilator effect than when either drug is utilized alone at its recommended dosage. Pharmacokinetics No pharmacokinetic studies have been carried out on levosalbutamol sulphate and ipratropium bromide combination. Hence pharmacokinetics of levosalbutamol sulphate and ipratropium bromide has been discussed individually. Levosalbutamol Information available in published literature suggests that the primary enzyme responsible for the metabolism of salbutamol enantiomers in humans is SULT1A3 (sulphotransferase). When racemic salbutamol was administered either intravenously or via inhalation after oral charcoal administration, there was a 3- to 4-fold difference in the area under the concentration time curves between the (R) - and (S)-salbutamol enantiomers, with (S)-salbutamol concentrations being consistently higher. However, without charcoal pre-treatment, after either oral or inhalation administration the differences were 8- to 24-fold, suggesting that (R)-salbutamol is preferentially metabolized in the gastrointestinal tract, presumably by SULT1A3. The primary route of elimination of salbutamol enantiomers is through renal excretion (80-100%) of either the parent compound or the primary metabolite. Less than 20% of the drug is detected in the faeces. Following intravenous administration of racemic salbutamol, between 25% and 46% of the (R)-salbutamol fraction of the dose was excreted as unchanged (R)-salbutamol in the urine. Special Populations Renal Impairment The effect of renal impairment on the pharmacokinetics of racemic salbutamol was evaluated in 5 subjects with creatinine clearance of 7-53 ml/min, and the results were compared with those from healthy volunteers. Renal disease had no effect on the half-life, but there was a 67% decline in racemic salbutamol clearance. Caution should be used when administering high doses of levosalbutamol Inhaler to patients with renal impairment. Hepatic Impairment The effect of hepatic impairment on the pharmacokinetics of levosalbutamol inhaler has not been evaluated. Ipratropium Bromide Absorption The therapeutic effect of Ipratropium is produced by a local action in the airways. Time courses of bronchodilation and systemic pharmacokinetics do not run in parallel. Following inhalation, 10 to 30% of a dose is generally deposited in the lungs, depending on the formulation, device and
3 inhalation technique. The major part of the dose is swallowed and passes through the gastro-intestinal tract. The portion of the dose deposited in the lungs reaches the circulation rapidly (within minutes). Cumulative renal excretion (0-24 hours) of parent compound is approximated to 46% of an intravenously administered dose, below 1% of an oral dose and approximately 3 to 13% of an inhaled dose. Based on these data the total systemic bioavailability of oral and inhaled doses of ipratropium bromide is estimated at 2% and 7 to 28% respectively. Taking this into account, swallowed dose portions of ipratropium bromide do not contribute significantly to systemic exposure. Distribution The drug is minimally (less than 20%) bound to plasma proteins. The quaternary amine of the ipratropium ion does not cross the blood-brain barrier. Biotransformation Ipratropium has a mean total clearance of 2.3 L/min and a renal clearance of 0.9 L/min. After intravenous administration approximately 60% of the dose is metabolised, mainly by conjugation (40%), whereas after inhalation about 77% of the systemically available dose is metabolised by ester hydrolysis (41%) and conjugation (36%). Elimination After inhalation of ipratropium bromide either with HFA or CFC propellant, cumulative renal excretion over 24 hours was approximately 12% and 10%, respectively. In an excretion balance study cumulative renal excretion (6 days) of drug-related radioactivity (including parent compound and all metabolites) accounted for 72.1% after intravenous administration, 9.3% after oral administration and 3.2% after inhalation. Total radioactivity excreted via the faeces was 6.3% following intravenous application, 88.5% following oral dosing and 69.4% after inhalation. Regarding the excretion of drug-related radioactivity after intravenous administration, the main excretion occurs via the kidneys. The half-life for elimination of drug-related radioactivity (parent compound and metabolites) is 3.2 hours. The main urinary metabolites bind poorly to the muscarinic receptor and have to be regarded as ineffective. Special Populations Geriatric Patients In the pharmacokinetic study with 29 COPD patients, a subset of 14 patients was >65 years of age. Mean peak plasma ipratropium concentrations of 56±24 pg/ml were obtained following a single administration of 4 inhalations (21 mcg/puff) of ipratropium bromide HFA Inhaler (84 mcg). When these 14 patients were administered 4 inhalations q.i.d. (16 inhalations/day) for 1 week, the mean peak plasma ipratropium concentration only increased to 84±50 pg/ml, indicating that the pharmacokinetic behaviour of ipratropium bromide in the geriatric population is consistent with younger patients. Indications DUOLIN rotacaps are indicated for use in patients with COPD, who are on a regular bronchodilator, or who continue to have evidence of bronchospasm and require a second bronchodilator. Dosage And Administration The dosage of DUOLIN rotacaps is 1 rotacap, four times a day. Patients may take additional inhalations as required; however, the total number of rotacaps should not exceed 6 in 24 hours. DUOLIN rotacaps should be used only with the Cipla Rotahaler/ Revolizer. DUOLIN rotacaps must not be swallowed.
4 Contraindications Hypersensitivity to any component of the formulation, or to atropine and its derivatives. Reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema. It is also contraindicated in patients with a history of hypersensitivity to soya lecithin or related food products such as soya bean and peanut. Warnings And Precautions Since DUOLIN rotacaps contains a combination of ipratropium bromide and levosalbutamol sulphate, the warnings and precautions for both drugs should be observed. Paradoxical Bronchospasm: DUOLIN rotacaps can produce paradoxical bronchospasm that can be life-threatening. If it occurs, the preparation should be discontinued immediately and alternative therapy instituted. Cardiovascular Effects Like other beta-adrenergic agonists, the levosalbutamol sulphate contained in DUOLIN rotacaps can produce clinically significant cardiovascular effects in some patients, as measured by pulse rate, blood pressure and/or symptoms. Although such effects are uncommon after administration of DUOLIN rotacaps at recommended doses, if they occur, discontinuation of the drug may be indicated. In addition, beta-adrenergic agents have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T-wave, prolongation of the QTc interval, and ST segment depression. Large doses of intravenous racemic salbutamol have been reported to aggravate pre-existing diabetes mellitus and ketoacidosis. Therefore, DUOLIN rotacaps should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension, in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines. Do Not Exceed Recommended Dose Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. The exact cause of death is unknown, but cardiac arrest following an unexpected development of a severe acute asthmatic crisis and subsequent hypoxia is suspected. Immediate Hypersensitivity Reactions Immediate hypersensitivity reactions may occur after administration of ipratropium bromide or levosalbutamol sulphate, as demonstrated by rare cases of urticaria (including giant urticaria), angio-oedema, skin rash, bronchospasm, anaphylaxis, oropharyngeal oedema, pruritus and laryngospasm. If such a reaction occurs, therapy with DUOLIN Rotacaps should be stopped at once and alternative treatment should be considered. Effects Seen with Anticholinergic Drugs DUOLIN rotacaps contain ipratropium bromide and may cause urinary obstruction and, therefore, should be used with caution in patients with narrow-angle glaucoma, prostatic hypertrophy, or bladder-neck obstruction. There have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, narrow-angle glaucoma, eye pain) when aerosolised ipratropium bromide, either alone or in combination with an adrenergic beta2-agonist, has come into contact with the eyes. Thus patients must be instructed in the correct administration of DUOLIN rotacaps and warned against the accidental release of the contents into the eye. Antiglaucoma therapy is effective in the prevention of acute
5 narrow-angle glaucoma in susceptible individuals and patients who may be susceptible to glaucoma should be warned specifically on the need for ocular protection. Eye pain or discomfort, blurred vision, visual halos or coloured images in association with red eyes from conjunctival congestion and corneal oedema may be signs of acute narrow-angle glaucoma. Should any combination of these symptoms develop, treatment with miotic drops should be initiated and specialist advice sought immediately. Effects Seen with Sympathomimetic Drugs Preparations containing sympathomimetic amines such as levosalbutamol sulphate should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines. Large doses of intravenous racemic salbutamol have been reported to aggravate preexisting diabetes mellitus and ketoacidosis. Additionally, beta-agonists may cause a decrease in serum potassium in some patients, possibly through intracellular shunting which has the potential to produce adverse cardiovascular effects. The decrease is usually transient, not requiring supplementation. Drug Interactions No formal drug interaction studies have been performed with DUOLIN rotacaps and these or other medications commonly used in the treatment of COPD. Anticholinergic Agents Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications. Caution is therefore advised in the co-administration of DUOLIN rotacaps with other anticholinergic-containing drugs. Beta-Adrenergic Agents Caution is advised in the co-administration of DUOLIN rotacaps and other sympathomimetic agents due to the increased risk of adverse cardiovascular effects. Beta-Receptor Blocking Agents These agents and levosalbutamol inhibit the effects of each other. Beta-receptor blocking agents should be used with caution in patients with hyper-reactive airways. Diuretics The ECG changes and/or hypokalaemia that may result from the administration of non-potassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonist-containing drugs, such as DUOLIN rotacaps, with non-potassium-sparing diuretics. Monoamine Oxidase Inhibitors or Tricyclic Antidepressants DUOLIN rotacaps should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of levosalbutamol on the cardiovascular system may be potentiated. Consider alternative therapy in patients taking MAO inhibitors or tricyclic antidepressants. Digoxin Mean decreases of 16% and 22% in serum digoxin levels were demonstrated after single-dose intravenous and oral administration of racemic salbutamol to normal volunteers who had receieved digoxin for 10 days; hence, it is advisable to carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and levosalbutamol. Renal Impairment DUOLIN rotacaps have not been studied in patients with renal impairment. It should be used with caution in these patient
6 populations. Racemic salbutamol is known to be substantially excreted by the kidney, and risk of toxic reactions may be greater in patients with renal impairment. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Hepatic Impairment DUOLIN rotacaps have not been studied in patients with hepatic impairment. It should be used with caution in these patient populations. Pregnancy There are no adequate and well-controlled studies of ipratropium bromide or levosalbutamol sulphate in pregnant women. Because animal reproduction studies are not always predictive of human response, DUOLIN rotacaps should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus. Lactation It is not known whether the components of DUOLIN rotacaps are excreted in human milk. DUOLIN rotacaps should not be used by breastfeeding mothers, unless the expected benefit is thought to outweigh the risks. The benefit: risk ratio when levosalbutamol is administered for tocolysis has not been established. Certain adverse reactions, such as maternal pulmonary edema, have been reported during or following treatment of premature labour with beta- 2- agonists, including racemic salbutamol. Undesirable Effects Since DUOLIN rotacaps contains both ipratropium and levosalbutamol, the side effects of both the components should be expected. Levosalbutamol side effects seen in adults and adolescents include tremor, pain, pharyngitis, rhinitis, nervousness, tachycardia, dizziness, headache, hypokalaemia, dry mouth, throat irritation, urinary retention, nausea, vomiting, sweating, weakness, myalgia/muscle cramps arrhythmia, anaphylactic reactions, cyst, flu syndrome, viral infection, constipation, gastroenteritis, myalgia, hypertension, epistaxis, lung disorder, acne, herpes simplex, conjunctivitis, ear pain, dysmenorrhea, hematuria, and vaginal moniliasis. In very rare instances, paradoxical bronchoconstriction has been observed. If, because of inappropriate handling, the DUOLIN rotacap powder enters the eyes in patients with narrowangle glaucoma, a rise in intraocular pressure may occur. In these cases, eye drops should be administered to induce miosis. Potentially serious hypokalaemia may result from beta 2 -agonist therapy. This effect may be potentiated by hypoxia. Particular caution is advised in severe asthma, along with monitoring of serum potassium levels. Other side effects such as palpitation, fine tremors of the skeletal muscle (particularly the hand) and muscle cramps may occur. In a few cases, nervousness, headache, dizziness, fatigue, and sleeplessness have also been reported. In addition to the adverse events reported in clinical trials, the following adverse events have been observed in post approval use of levosalbutamol. These events have been chosen for inclusion due to their seriousness, their frequency of reporting, or their likely beta-mediated mechanism: angioedema, anaphylaxis, arrhythmias (including atrial fibrillation, supraventricular tachycardia, and extra systoles), asthma, chest pain, cough increased, dyspnea, nausea, nervousness, rash, tachycardia, tremor, and urticaria. Because these events have been reported spontaneously from a population of unknown size, estimates of frequency cannot be made. In addition, levosalbutamol, like other sympathomimetic agents, can cause adverse reactions such as hypertension,
7 angina, vertigo, central nervous system stimulation, sleeplessness, headache, and drying or irritation of the oropharynx. Ipratropium Bromide The following side effects have been reported during treatment with ipratropium bromide. The frequencies given below are based on clinical trials involving patients who have been treated with ipratropium. Frequencies Very common 1/10 1/100 < 1/10 1/1,000< 1/100 Rare 1/10,000 < 1/1,000 Very rare < 1/10,000 Immune system disorders Hypersensitivity Anaphylactic reaction Angio-oedema of tongue, lips, face Nervous system disorders Headache Dizziness Eye disorders Blurred vision Glaucoma (1) Intraocular pressure increased (1) Eye pain (1) Mydriasis (1) Halo vision Conjunctival hyperaemia Corneal oedema Accommodation disorder Rare Cardiac Disorders Increased heart rate Palpitations Rare
8 Supraventricular tachycardia Atrial fibrillation Rare Respiratory, Thoracic and Mediastinal Disorders Cough Pharyngeal oedema Dry throat Bronchospasm Throat irritation Paradoxical bronchospasm (2) Laryngospasm Gastro-intestinal Disorders Dryness of mouth Vomiting Gastro-intestinal motility disorder e.g. Diarrhoea Constipation Nausea Stomatitis Skin and Subcutaneous Disorders Skin rash Pruritus Urticaria Rare Renal and Urinary Disorders Urinary retention (3) (1) ocular complications have been reported when aerolised ipratropium bromide, either alone or in combination with an adrenergic beta2-agonist, has come into contact with the eyes during nebuliser therapy (2) as with other inhalation therapy, inhalation induced bronchoconstriction may occur with an immediate increase in wheezing after dosing. This should be treated straight away with a fast acting inhaled bronchodilator. DUOLIN inhaler should be discontinued immediately, the patient assessed and, if necessary, alternative treatment instituted. (3) the risk of urinary retention may be increased in patients with pre-existing urinary outflow tract obstruction. Other side-effects include urticaria including giant urticaria, hypotension back pain, headache, influenza-like symptoms, dizziness, dyspepsia, bronchitis, COPD exacerbations, dyspnea, sinusitis and urinary tract infection.
9 Other side-effects that have been reported include urticaria including giant urticaria, hypotension back pain, headache, influenza-like symptoms, dizziness, dyspepsia, bronchitis, COPD exacerbations, dyspnea, sinusitis and urinary tract infection. In a 5-year placebo-controlled trial, hospitalizations for supraventricular tachycardia and/or atrial fibrillation occurred with an incidence rate of 0.5% in COPD patients receiving ipratropium CFC. Additionally, urinary retention, mydriasis, gastrointestinal distress (diarrhoea, nausea, vomiting), cough and bronchospasm, including paradoxical bronchospasm, hypersensitivity reactions, intraocular pressure increased, accommodation disorder, heart rate increased, pharyngeal edema, and gastrointestinal motility disorders have been reported during the post-marketing period with use of ipratropium. Overdosage Levosalbutamol The expected symptoms with overdosage are those of excessive beta-adrenergic receptor stimulation and/or occurrence or exaggeration of any of the symptoms listed under adverse reactions, e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/minute, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, and sleeplessness. Hypokalaemia may also occur. As with all sympathomimetic medications, cardiac arrest and, even, death may be associated with the abuse of levosalbutamol. Treatment consists of discontinuation of levosalbutamol together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial in treating overdosage of levosalbutamol. Ipratropium Bromide Acute overdose by inhalation is unlikely since ipratropium bromide is not well absorbed systemically after inhalation or oral administration. Immediate hypersensitivity reactions may occur after administration of ipratropium bromide, as demonstrated by rare cases of urticaria, angio-oedema, rash, bronchospasm, anaphylaxis, and oropharyngeal oedema. Packaging Information DUOLIN Rotacaps Each sales pack contains 30 rotacaps Last Updated: Jul 2015 Last Reviewed: Jul 2015 DUOLIN Rotacaps Source URL:
IPRAVENT Rotacaps (Ipratropium bromide)
Published on: 10 Jul 2014 IPRAVENT Rotacaps (Ipratropium bromide) Composition IPRAVENT Rotacaps Each capsule contains: Ipratropium Bromide BP, equivalent to Ipratropium Bromide (anhydrous) 40 mcg Excipient..q.s.
More informationIPRAVENT Respules/Respirator solution (Ipratropium bromide)
Published on: 19 Sep 2014 IPRAVENT Respules/Respirator solution (Ipratropium bromide) Composition IPRAVENT Respules Each 2 ml contains: Ipratropium Bromide BP equivalent to Ipratropium Bromide (anhydrous)
More informationDUOLIN Respules (Levosalbutamol sulphate + Ipratropium bromide)
Published on: 10 Jul 2014 DUOLIN Respules (Levosalbutamol sulphate + Ipratropium bromide) Composition DUOLIN Respules Each 2.5 ml unit-dose vial contains: Levosalbutamol sulphate.1.25 mg Ipratropium bromide
More informationComposition Each ml of Ventol solution for inhalation contains 5 mg Salbutamol (as sulphate).
VENTOL Composition Each ml of Ventol solution for inhalation contains 5 mg Salbutamol (as sulphate). Respiratory Solution Action Salbutamol is a short-acting, relatively selective beta2-adrenoceptor agonist.
More informationCOMBIVENT Metered Aerosol Boehringer
COMBIVENT Metered Aerosol Boehringer Composition 1 metered dose contains: (8r)-3*-Hydroxy-8-isopropyl-1*,5*-tropanium bromide (±)-tropate monohydrate (= ipratropium bromide monohydrate) 21 mcg equivalent
More informationAEROCORT Inhaler (Beclomethasone dipropionate + Levosalbutamol)
Published on: 28 Jan 2016 AEROCORT Inhaler ( + ) Composition Each actuation delivers: IP. 50 mcg sulphate IP equivalent to levosalbutamol..50 mcg Suspended in propellant HFA-134a.. q.s. Dosage Form Inhalation
More informationASTHALIN Respirator Solution (Salbutamol sulphate)
Published on: 28 Jan 2016 ASTHALIN Respirator Solution (Salbutamol sulphate) Composition Each 1 ml contains: Salbutamol Sulphate IP equivalent to Salbutamol IP.. 5 mg Dosage Form Solution for inhalation
More informationPRODUCT INFOMATION APO-IPRATROPIUM SOLUTION
PRODUCT INFOMATION APO-IPRATROPIUM SOLUTION NAME OF THE MEDICINE Ipratropium bromide. Chemical Name: (1R,3r,5S,8r)-3-[[(2RS)-3-Hydroxy-2-phenylpropanoyl]oxy]-8-methyl-8-(1- methylethyl)-8-azoniabicyclo[3.2.1]octane
More informationPRODUCT INFORMATION. IPRAVENT Inhalation Solution Unit Dose NAME OF THE MEDICINE DESCRIPTION. Ipratropium Bromide BP
PRODUCT INFORMATION IPRAVENT Inhalation Solution Unit Dose NAME OF THE MEDICINE Ipratropium Bromide BP Ipratropium bromide is a quaternary isopropyl derivative of atropine. Its chemical name is (1R, 3r,
More informationPACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP
PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP Brand or Product Name [Product name] Tablet 2mg [Product name] Tablet 4mg [Product name] Syrup 2mg/5ml Name and Strength of Active Substance(s)
More informationPRODUCT INFORMATION. IPRAVENT Inhalation Solution Multi Dose NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY. Ipratropium Bromide BP
PRODUCT INFORMATION IPRAVENT Inhalation Solution Multi Dose NAME OF THE MEDICINE Ipratropium Bromide BP Ipratropium bromide is a quaternary isopropyl derivative of atropine. Its chemical name is (1R, 3r,
More informationSEROBID Inhaler (Salmeterol xinafoate)
Published on: 10 Jul 2014 SEROBID Inhaler (Salmeterol xinafoate) Composition Each actuation delivers: Salmeterol (as Salmeterol Xinafoate IP) 25 mcg Suspended in propellant HFA 134a.....q.s. Dosage Form
More informationASTHALIN Respules (Salbutamol sulphate)
Published on: 28 Jan 2016 ASTHALIN Respules (Salbutamol sulphate) Composition Each 2.5 ml respule contains: Salbutamol Sulphate IP equivalent to Salbutamol IP. 2.5 mg Normal saline solution.q.s. Dosage
More informationUtibron Neohaler. (indacaterol, glycopyrrolate) New Product Slideshow
Utibron Neohaler (indacaterol, glycopyrrolate) New Product Slideshow Introduction Brand name: Utibron Neohaler Generic name: Indacaterol, glycopyrrolate Pharmacological class: Long-acting beta2- agonist
More informationTIOVA Inhaler (Tiotropium bromide)
Published on: 18 Sep 2014 TIOVA Inhaler (Tiotropium bromide) Composition TIOVA Inhaler Each actuation delivers: Tiotropium Bromide Monohydrate IP equivalent to Tiotropium... 9 mcg Suspended in propellant
More informationATROVENT Metered Aerosol (CFC-free)
NAME OF THE DRUG ATROVENT Metered Aerosol (CFC-free) Atrovent metered aerosol contains the active ingredient ipratropium bromide. DESCRIPTION Ipratropium bromide is a synthetic quaternary ammonium compound,
More informationSalapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup.
Salapin Salbutamol Syrup 2mg/5mL Qualitative and quantitative composition Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup. Clinical particulars Therapeutic
More informationVENTOLIN RESPIRATOR SOLUTION
VENTOLIN RESPIRATOR SOLUTION Salbutamol QUALITATIVE AND QUANTITATIVE COMPOSITION VENTOLIN Respirator Solution contains 5mg salbutamol, as sulphate, per ml of solution and is supplied in 10 ml bottles.
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Summary of Product Characteristics Combivent UDVs 500 micrograms/2.5mg per 2.5ml Nebuliser Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2.5ml single dose unit
More informationTERBUTALINE SULFATE INJECTION, USP
451001C/Revised: March 2008 TERBUTALINE SULFATE INJECTION, USP Rx only A sterile aqueous solution for subcutaneous injection. DESCRIPTION: Terbutaline Sulfate Injection, USP, is a beta-adrenergic agonist
More informationA COPD medication delivery device option: an overview of the NEOHALER
A COPD medication delivery device option: an overview of the NEOHALER 2017 Sunovion Pharmaceuticals Inc. All rights reserved 9/17 RESP019-17 Indication and Boxed Warning INDICATION ARCAPTA NEOHALER (indacaterol)
More informationATROVENT NASAL and ATROVENT NASAL FORTE PRODUCT INFORMATION
ATROVENT NASAL and ATROVENT NASAL FORTE PRODUCT INFORMATION DESCRIPTION Approved Name Chemical Name Ipratropium bromide (1R, 3r, 5S, 8r)-8-Isopropyl-3-( tropoyloxytropanium bromide. C 20 H 30 NO 3 Br.
More informationCombivent Unit Dose Vials
Combivent Unit Dose Vials Composition 1 unit-dose vial (2.5 ml) solution for inhalation contains: Ipratropium bromide corresponding to 0.5 mg ipratropium bromide anhydrous 0.52 mg Salbutamol sulphate corresponding
More informationDUOVA Rotacaps (Tiotropium bromide monohydrate + Formoterol fumarate dihydrate)
Published on: 10 Jul 2014 DUOVA Rotacaps (Tiotropium bromide monohydrate + Formoterol fumarate dihydrate) Black Box Warning: Asthma-Related Death Long-acting beta 2 -adrenergic agonists (LABA) increase
More information7.2 Part VI.2 Elements for a Public Summary
7.2 Part VI.2 Elements for a Public Summary 7.2.1 Part VI.2.1 Overview of disease epidemiology Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation that is usually
More informationNEW ZEALAND DATA SHEET SEREVENT Accuhaler
NEW ZEALAND DATA SHEET SEREVENT Accuhaler Salmeterol xinafoate (50 mcg per inhalation) Presentation SEREVENT Accuhaler is a moulded plastic device containing a foil strip with 60 regularly placed blisters
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR:
Core Safety Profile Active substance: Carteolol Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% P - RMS: SK/H/PSUR/0002/002 Date of FAR: 16.03.2012 4.1 THERAPEUTIC INDICATIONS Ocular hypertension
More informationTERBUTALINE SULFATE INJECTION, USP
451001D/Revised: February 2011 TERBUTALINE SULFATE INJECTION, USP Rx only A sterile aqueous solution for subcutaneous injection. WARNING: PROLONGED TOCOLYSIS Terbutaline sulfate has not been approved and
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Salbuvent 5 mg/2.5 ml Nebuliser Solution Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ampoule contains 5mg salbutamol (as sulphate).
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationPRODUCT INFORMATION. SUDAFED Sinus 12 Hour Relief Tablets
PRODUCT INFORMATION SUDAFED Sinus 12 Hour Relief Tablets NAME OF THE MEDICINE Pseudoephedrine Hydrochloride CAS 2 Registry Number: 345-78-8 DESCRIPTION SUDAFED Sinus 12 Hour Relief prolonged-release tablets
More informationPRODUCT INFORMATION VENTOLIN ROTACAPS
PRODUCT INFORMATION VENTOLIN ROTACAPS APPROVED NAME: Salbutamol sulphate B.P. PHYSICAL AND CHEMICAL CHARACTERISTICS: Salbutamol sulphate is a white or almost white odourless powder. It is soluble in 4
More informationBRICANYL INJECTION. terbutaline sulfate PRODUCT INFORMATION
BRICANYL INJECTION terbutaline sulfate PRODUCT INFORMATION NAME OF THE MEDICINE Terbutaline sulfate, 2-(tert-butylamino)-1-(3,5-dihydroxyphenyl) ethanol sulfate, a sympathomimetic bronchodilator with a
More informationPRODUCT INFORMATION. Ammonium chloride is an expectorant that has an irritant effect on mucous membranes.
PRODUCT INFORMATION BENADRYL Original Oral Liquid (New Formula) Name of the Medicine Diphenhydramine hydrochloride Ammonium chloride The chemical name for diphenhydramine hydrochloride is 2-(diphenylmethoxy)-N,Ndimethylethanamine
More informationPharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS:
0BCore Safety Profile Active substance: Betaxolol eyedrops Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS: HU/H/PSUR/0010/002 Date of FAR: 20.03.2013 4.2 Posology
More information14 41 minutes Vd 218 t ½ 22 to 70 Clearance hours Protein Binding 71%, active metabolite 42% Bioavailability 3%
Brand Name: Yupelri Generic Name: revefenacin Manufacturer: Mylan Drug Class: Anticholinergic Uses: Labeled Uses: inhalation solution for maintenance treatment of COPD 1 Unlabeled Uses: no off-label indications
More informationPRODUCT INFORMATION VENTOLIN DISKS
PRODUCT INFORMATION VENTOLIN DISKS APPROVED NAME: Salbutamol sulphate B.P. PHYSICAL AND CHEMICAL CHARACTERISTICS: Salbutamol sulphate is a white or almost white odourless powder. It is soluble in 4 parts
More informationCHESTON PLUS Syrup (Ambroxol hydrochloride + Terbutaline sulphate + Guaiphenesin)
Published on: 22 Sep 2014 CHESTON PLUS Syrup ( hydrochloride + sulphate + ) Composition Each 5 ml contains: hydrochloride... 15 mg sulphate IP...1.25 mg IP...50 mg Menthol IP...1 mg Flavoured syrup base...
More informationChronic obstructive pulmonary disease (COPD) is a progressive,
INFORMATION for the PHARMACIST This article was sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. Improving Lung Function (FEV 1 ) in COPD Through Appropriate Counseling on Use of Inhaled Medications
More informationAtrovent HFA (ipratropium bromide HFA) Inhalation Aerosol
ATTENTION PHARMACIST: Detach "Patient's Instructions for Use" from package insert and dispense with the product. Atrovent HFA (ipratropium bromide HFA) Inhalation Aerosol For Oral Inhalation Only Rx only
More informationFLOMIST Aqueous Nasal Spray (Fluticasone propionate)
Published on: 10 Jul 2014 FLOMIST Aqueous Nasal Spray (Fluticasone propionate) Composition FLOMIST Aqueous Nasal Spray Each spray delivers: Fluticasone Propionate BP...50 mcg Fluticasone Propionate BP...
More informationOXIS TURBUHALER 4.5 µg/dose and 9 µg/dose ASTRAZENECA
10-14 OXIS TURBUHALER 4.5 µg/dose and 9 µg/dose ASTRAZENECA formoterol fumarate dihydrate Inhalation powder Composition Each delivered dose (i.e. the dose leaving the mouthpiece) from Oxis Turbuhaler contains
More informationReference ID: Page 1
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COMBIVENT RESPIMAT safely and effectively. See full prescribing information for COMBIVENT RESPIMAT.
More informationNEW ZEALAND DATA SHEET ACUPAN TM. 3. PHARMACEUTICAL FORM White, round, biconvex, film-coated tablets (7 mm diameter) engraved APN on one face.
1. PRODUCT NAME ACUPAN 30 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains nefopam hydrochloride 30 mg. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM
More informationSUMMARY OF PRODUCT CHARACTERISTICS
MUTUAL RECOGNITION PROCEDURE Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT, syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of syrup contains 1 mg loratadine.
More informationPRODUCT MONOGRAPH. (salbutamol sulphate and ipratropium bromide Nebulizer Solution)
PRODUCT MONOGRAPH Pr TEVA-COMBO STERINEBS (salbutamol sulphate and ipratropium bromide Nebulizer Solution) Each Unit Dose Vial (UDV) contains 0.50 mg of ipratropium bromide (as ipratropium bromide monohydrate)
More informationNEW ZEALAND DATA SHEET. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each metered dose contains terbutaline sulphate 250 µg.
NEW ZEALAND DATA SHEET 1. PRODUCT NAME BRICANYL TURBUHALER, Inhalation powder, 250 µg/dose 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each metered dose contains terbutaline sulphate 250 µg. For a full
More informationRESPIRATORY PHARMACOLOGY - ASTHMA. Primary Exam Teaching - Westmead ED
RESPIRATORY PHARMACOLOGY - ASTHMA Primary Exam Teaching - Westmead ED Sympathomimetic agents MOA: relax airway smooth muscle and inhibit broncho constricting mediators from mast cells May also inhibit
More informationPRODUCT MONOGRAPH. Indacaterol (as maleate)/glycopyrronium (as bromide) inhalation powder hard capsules. 110 mcg/50 mcg per capsule
PRODUCT MONOGRAPH Pr ULTIBRO BREEZHALER Indacaterol (as maleate)/glycopyrronium (as bromide) inhalation powder hard capsules 110 mcg/50 mcg per capsule ULTIBRO BREEZHALER capsules to be used only with
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME Sudomyl, Tablet, 60 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Name and strength of the active substance Pseudoephedrine Hydrochloride 60mg Excipient(s) with known effect For the full
More informationNew Zealand Datasheet
New Zealand Datasheet 1 PRODUCT NAME Asthalin 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Salbultamol respiratory solution 3 PHARMACEUTICAL FORM Asthalin is a plastic ampoule presentation containing a sterile,
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET NAME OF MEDICINE OXIS TURBUHALER Eformoterol fumarate dihydrate (6 µg per inhalation) PRESENTATION OXIS TURBUHALER is a multidose, inspiratory flow driven, metered dose, dry powder
More informationChemical name: di[(rs)-2-(1,1-dimethyl)ethylamino-1-[4-hydroxy-3- (hydroxymethyl)phenyl]ethanol] sulphate
Product Information Page 1 PRODUCT INFORMATION SALBUTAMOL SANDOZ 2.5MG/2.5ML, 5MG/2.5ML INHALATION AMPOULES NAME OF THE MEDICINE Generic name: Salbutamol sulphate BP Chemical name: di[(rs)-2-(1,1-dimethyl)ethylamino-1-[4-hydroxy-3-
More informationPROVENTIL HFA - albuterol sulfate aerosol, with Dose Indicator Merck Sharp & Dohme Corp
1 2 3 4 5 6 7 8 9 10 11 12 PROVENTIL HFA - albuterol sulfate aerosol, with Dose Indicator Merck Sharp & Dohme Corp. ------------------------------ PROVENTIL HFA (albuterol sulfate) Inhalation Aerosol with
More informationPRODUCT MONOGRAPH. Ipratropium Bromide (as Monohydrate) and Salbutamol (as Salbutamol Sulfate) Nebulizer Solution
PRODUCT MONOGRAPH Pr COMBIVENT UDV Ipratropium Bromide (as Monohydrate) and Salbutamol (as Salbutamol Sulfate) Nebulizer Solution Each Unit Dose Vial (UDV) contains 0.50 mg of ipratropium bromide (as ipratropium
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Otrivin Menthol (without preservative) 1.0 mg/ml nasal spray, solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 1.0 mg
More informationComposition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties:
Composition: Each tablet contain Montelukast Levocetirizine 10mg 5mg Each 5ml contains Montelukast Levocetirizine 4mg 2.5mg Pharmacokinetic properties: Peak plasma concentrations of montelukast are achieved
More informationSUMMARY OF PRODUCT CHARACTERISTICS Version: March 2006
SUMMARY OF PRODUCT CHARACTERISTICS Version: March 2006 1. NAME OF THE MEDICINAL PRODUCT FAVINT 18 microgram, inhalation powder, hard capsule 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR:
Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications
More informationDeveloped By Name Signature Date
Patient Group Direction 2156 version 2.0 Administration of Ipratropium 250mcg/ml Nebuliser Solution in Acute Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Date of
More informationBUDESAL Respules (Budesonide + Levalbuterol)
Published on: 10 Jul 2014 BUDESAL Respules (Budesonide + Levalbuterol) Composition BUDESAL 0.5 Respules Each 2 ml respule contains: Levalbuterol Sulphate, equivalent to levalbuterol.1.25 mg Budesonide
More informationAsmol uni-dose Salbutamol (sulfate) PRODUCT INFORMATION
Asmol uni-dose Salbutamol (sulfate) PRODUCT INFORMATION NAME OF MEDICINE The active ingredient of Asmol uni-dose is salbutamol (as sulfate). The chemical name for salbutamol sulfate is: 1-(4-hydroxy-3-hydroxymethylphenyl)-2-(t-butylamino)ethanol
More informationPRODUCT INFORMATION VENTOLIN ROTACAPS. The chemical name of salbutamol sulfate is 1-(4-hydroxy-3-hydroxymethylphenyl)-2-(tertbutylamino)ethanol
PRODUCT INFORMATION VENTOLIN ROTACAPS NAME OF THE MEDICINE: Ventolin Rotacaps Ventolin Rotacaps contain salbutamol (as sulfate) B.P. The chemical name of salbutamol sulfate is 1-(4-hydroxy-3-hydroxymethylphenyl)-2-(tertbutylamino)ethanol
More information1. NAME OF THE MEDICINAL PRODUCT. Vicks Sinex, 0.5 mg/ml, nasal spray solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
1. NAME OF THE MEDICINAL PRODUCT Vicks Sinex, 0.5 mg/ml, nasal spray solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Oxymetazoline hydrochloride 0.5 mg/ml 1 spray (50 l) contains approximately 25
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Date: May 02, 2005
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Date: May 02, 2005 SPCBerodualRespimat 1 1. NAME OF THE MEDICINAL PRODUCT Berodual Respimat 20/50 microgram/dose, solution for inhalation 2. QUALITATIVE AND QUANTITATIVE
More informationTRIOHALE Inhaler (Tiotropium bromide + Formoterol fumarate + Ciclesonide)
Published on: 20 Sep 2014 TRIOHALE Inhaler ( bromide + fumarate + ) Composition TRIOHALE Inhaler Each puff contains: Bromide monohydrate equivalent to...9 mcg Fumarate Dihydrate IP.....6mcg IP...200 mcg
More informationRespiratory Pharmacology. Manuel Otero Lopez Department of Anaesthetics and Intensive Care Hôpital Européen Georges Pompidou, Paris, France
Respiratory Pharmacology Manuel Otero Lopez Department of Anaesthetics and Intensive Care Hôpital Européen Georges Pompidou, Paris, France Programme Bronchomotor tone Drugs and factors influencing airway
More informationVESIGARD Tablets (Darifenacin hydrobromide)
Published on: 10 Jul 2014 VESIGARD Tablets (Darifenacin hydrobromide) Composition VESIGARD 7.5 Extended Release Tablets Each tablet contains: Darifenacin (as a hydrobromide).. 7.5 mg Dosage Form Tablets
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Prolonged release tablets, 4 mg and 8 mg (GITS) Date of FAR:
Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Prolonged release tablets, 4 mg and 8 mg (GITS) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications
More informationAtrovent Administration
Atrovent Administration ICEMA Training 2007 Sherri Shimshy RN OBJECTIVES Describe the pharmacology of Atrovent Identify the indications for use of Atrovent in the Adult Population Identify the indications
More informationGlaxoSmithKline. Renal impairment. Hepatic impairment
RELENZA GlaxoSmithKline Zanamivir QUALITATIVE AND QUANTITATIVE COMPOSITION Each RELENZA ROTADISK consists of four regularly spaced double foil blisters each containing a white to off-white micronised powder
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Otrivin Comp 0.5 mg/ml + 0.6 mg/ml nasal spray, solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 0.5 mg xylometazoline
More informationGenRx SALBUTAMOL INHALATION AMPOULE
GenRx SALBUTAMOL INHALATION AMPOULE NAME OF THE MEDICINE Salbutamol sulfate. Chemical Name: di[(rs)-2-(1,1-dimethyl)ethylamino-1-[4-hydroxy-3- (hydroxymethyl)phenyl]ethanol] sulfate. Structural Formula:
More informationLevocetirizine dihydrochloride
INSERT TEXT UAP Levocetirizine dihydrochloride Allerzet 5 mg Tablet Antihistamine FORMULATION Each film-coated tablet contains: Levocetirizine dihydrochloride.. 5 mg PRODUCT DESCRIPTION Levocetirine 5
More informationNAPHCON-A Eye Drops naphazoline hydrochloride 0.025% and pheniramine maleate 0.3%.
NEW ZEALAND DATA SHEET 1. PRODUCT NAME NAPHCON-A Eye Drops naphazoline hydrochloride 0.025% and pheniramine maleate 0.3%. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Naphcon-A contains naphazoline hydrochloride
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fexofenadine Cipla 120 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 120 mg fexofenadine
More informationMigraleve, Migraleve Pink and Migraleve Yellow Product Information
Migraleve, Migraleve Pink and Migraleve Yellow Product Information Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also
More information*Sections or subsections omitted from the full prescribing information are not listed.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROAIR DIGIHALER safely and effectively. See full prescribing information for PROAIR DIGIHALER. PROAIR
More informationSummary of the risk management plan (RMP) for Duaklir Genuair (aclidinium / formoterol fumarate dihydrate)
EMA/605453/2014 Summary of the risk management plan (RMP) for Duaklir Genuair (aclidinium / formoterol fumarate dihydrate) This is a summary of the risk management plan (RMP) for Duaklir Genuair, which
More informationFURAMIST Nasal Spray (Fluticasone furoate )
Published on: 21 Jan 2016 FURAMIST Nasal Spray (Fluticasone furoate ) Composition Each spray contains: Fluticasone furoate 27.5 mcg Dosage Form Aqueous intranasal spray Pharmacology Pharmacodynamics Fluticasone
More informationChapter 55. Changes in the Airway With COPD. Manifestations of Severe COPD. Drugs Used to Treat Obstructive Pulmonary Disorders
Chapter 55 Drugs Used to Treat Obstructive Pulmonary Disorders Changes in the Airway With COPD Manifestations of Severe COPD Air is trapped in the lower respiratory tract The alveoli degenerate and fuse
More informationAXALIN Expectorant (Ambroxol hydrochloride + Terbutaline sulphate + Guaiphenesin)
Published on: 27 Jan 2016 AXALIN Expectorant ( hydrochloride + sulphate + ) Composition Each 5 ml contains: hydrochloride.. 15 mg sulphate IP...1.25 mg IP...50 mg Menthol IP...1 mg Flavoured syrup base...
More informationNew Zealand Data Sheet
New Zealand Data Sheet 1 PRODUCT NAME Salair 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Pressurised metered-dose inhaler (pmdi) containing Salbutamol sulphate (equivalent to 100mcg salbutamol base per
More informationVENTOLIN EVOHALER. Salbutamol
VENTOLIN EVOHALER CFC FREE Salbutamol QUALITATIVE AND QUANTITATIVE COMPOSITION VENTOLIN EVOHALER is a pressurised metered-dose inhaler which delivers 100 mcg salbutamol (as sulphate) per actuation, into
More informationALFUSIN Tablets (Alfuzosin hydrochloride)
Published on: 20 Sep 2014 ALFUSIN Tablets (Alfuzosin hydrochloride) Composition Each film-coated extended-release tablet contains: Alfuzosin hydrochloride Ph.Eur... 10 mg Dosage Form Extended-release tablet
More informationOXYSPAS Tablets (Oxybutynin chloride)
Published on: 10 Jul 2014 OXYSPAS Tablets (Oxybutynin chloride) Composition OXYSPAS-2.5 Tablets Each uncoated tablet contains Oxybutynin chloride... 2.5 mg OXYSPAS-5 Tablets Each uncoated tablet contains
More informationPRODUCT INFORMATION. Sudafed* Sinus + Anti-inflammatory Pain Relief Caplets
PRODUCT INFORMATION Sudafed* Sinus + Anti-inflammatory Pain Relief Caplets Product description Sudafed* Sinus + Anti-inflammatory Pain Relief caplets contain pseudoephedrine hydrochloride 30 mg and ibuprofen
More informationPRODUCT INFORMATION VENTOLIN RESPIRATOR SOLUTION AND NEBULES
PRODUCT INFORMATION VENTOLIN RESPIRATOR SOLUTION AND NEBULES APPROVED NAME: Salbutamol Sulphate BP PHYSICAL AND CHEMICAL CHARACTERISTICS: Salbutamol sulphate is a white or almost white odourless powder.
More informationPRODUCT INFORMATION. 1-(4-hydroxy-3-hydroxymethylphenyl)-2-(t-butylamino)ethanol Sulphate.
PRODUCT INFORMATION VENTOLIN RESPIRATOR SOLUTION AND NEBULES NAME OF THE MEDICINE: Salbutamol Sulphate BP Chemical Name: 1-(4-hydroxy-3-hydroxymethylphenyl)-2-(t-butylamino)ethanol Sulphate. Structure:
More informationPROAIR HFA (albuterol sulfate) INHALATION AEROSOL Initial U.S. Approval: RECENT MAJOR CHANGES Dosage and Administration 07/2010
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROAIR HFA safely and effectively. See full prescribing information for PROAIR HFA Inhalation Aerosol.
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Aciclovir Pharmaceutical form(s)/strength: Tablets 200, 400 or 800 mg Dispersible tablets 200, 400 or 800 mg Oral suspensions 200 mg or 400 mg per 5 ml. Freeze
More informationPRODUCT MONOGRAPH SPIRIVA. Tiotropium Capsules for Oral Inhalation (18 μg tiotropium per capsule as tiotropium bromide monohydrate)
PRODUCT MONOGRAPH Pr SPIRIVA Tiotropium Capsules for Oral Inhalation (18 μg tiotropium per capsule as tiotropium bromide monohydrate) Capsules to be used only with the supplied HandiHaler inhalation device
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fexofenadine hydrochloride 180 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains 180mg
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Dry Powder Inhaler, Nebuliser Suspension, pressurised Metered Dose Inhaler (pmdi)
Core Safety Profile Active substance: Budesonide Pharmaceutical form(s)/strength: Dry Powder Inhaler, Nebuliser Suspension, pressurised Metered Dose Inhaler (pmdi) P - RMS: DK/H/PSUR/0041/001 Date of FAR:
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Capsules, 0.5 mg AT/H/PSUR/0028/001 Date of FAR:
Core Safety Profile Active substance: Anagrelide hydrochloride Pharmaceutical form(s)/strength: Capsules, 0.5 mg P-RMS: AT/H/PSUR/0028/001 Date of FAR: 02.08.2010 4.3 Contraindications Hypersensitivity
More informationTILAZEM. Diltiazem hydrochloride 240 mg
Tilazem Capsules Page 1 of 9 TILAZEM Diltiazem hydrochloride SCHEDULING STATUS: S3 PROPRIETARY NAME (AND DOSAGE FORM): TILAZEM 180 CR (controlled-release capsule) TILAZEM 240 CR (controlled-release capsule)
More informationBody weight more than 30kg : 10ml (10mg) of the syrup once daily.
1. Name of the medicinal product Clarityn Allergy 1mg/ml Syrup 2. Qualitative and quantitative composition Each ml of syrup contains 1mg loratadine. Excipients with known effect. The quantity of sucrose
More information